Fat Loss Research Stack

Fat Loss Stack – Retatrutide 10 mg + 5‑Amino‑1MQ 50 mg

The Fat Loss Stack pairs a 10 mg vial of Retatrutide with a 50 mg vial of 5‑Amino‑1MQ, creating a dual‑pathway research toolkit for investigating body‑weight reduction, fat‑mass changes, and metabolic health in preclinical and exploratory models. This combination is structured for weight‑loss‑focused research only and is not intended as a clinical weight‑management product.

What’s included

• 1 x Retatrutide – 10 mg lyophilized peptide vial

• 1 x 5‑Amino‑1MQ – 50 mg small‑molecule vial

Both are supplied as high‑purity research compounds intended for reconstitution and use under controlled laboratory conditions.

Mechanistic focus

• Retatrutide (10 mg)

A next‑generation triple incretin agonist candidate acting at GIP, GLP‑1, and glucagon receptors, used in research on appetite regulation, gastric emptying, glucose control, and energy expenditure. It anchors the stack’s hormonal and whole‑body weight‑loss arm, making it suitable for diet‑induced obesity and insulin‑resistance models.

• 5‑Amino‑1MQ (50 mg)

A selective NNMT (nicotinamide N‑methyltransferase) inhibitor used to explore changes in adipocyte size, fat storage, resting energy expenditure, and NAD⁺‑linked cellular metabolism. It supports the cellular and adipose‑tissue remodeling side of weight‑loss research.

In combination, these two agents allow investigators to study how modifying incretin signaling and NNMT‑driven nicotinamide metabolism together may impact weight, fat distribution, and metabolic markers more than targeting either pathway alone.

Research applications

This Fat Loss Stack is intended for:

• Weight‑loss and obesity models

Tracking body‑weight trajectory, fat‑mass vs lean‑mass changes, waist/visceral fat surrogates, and re‑gain dynamics after intervention withdrawal.

• Insulin resistance and metabolic health

Assessing fasting glucose and insulin, tolerance tests, lipid panels, and other cardiometabolic markers under combined incretin and NNMT modulation.

• Adipose‑tissue biology

Evaluating adipocyte size, tissue histology, inflammatory markers, and expression of genes involved in lipolysis, lipogenesis, and energy expenditure.

Handling and storage

• For laboratory research use only, by trained professionals.

• Store vials in a cool, dry environment away from light.

• Follow your lab’s SOPs for peptide and small‑molecule reconstitution, aliquoting, labeling, and disposal.

• Study design (dose, frequency, timing vs feeding, study duration) should be based on current literature for each compound and the specific weight‑loss model employed.

Important disclaimer

All compounds sold by Rocky Peptide Chain, including the Fat Loss Stack (Retatrutide 10 mg and 5‑Amino‑1MQ 50 mg), are for research use only. They are not intended for human consumption, medical use, diagnostic purposes, or treatment of any disease or condition. No claims are made or implied regarding clinical weight loss, body‑recomposition, blood‑sugar control, or therapeutic benefit. Researchers are solely responsible for appropriate handling, experimental design, and compliance with all applicable regulations.